Dr Ross Davey

Director, Bill Walsh Cancer Research Laboratories
Medicine, Northern Clinical School

E25 - Royal North Shore Hospital
The University of Sydney
NSW 2006 Australia

T: +61 2 9926 4727
F: +61 2 9926 5253

On this page

Themes | Keywords | Publications



Lung cancer; Vaccines and vaccinology; Breast cancer; Brain tumours; Proteomics


2014 | 2012 | 2009 | 2008


  • Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014), Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research. 2(5), 469-479. [Abstract]


  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012), The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer. 75(2), 248-254. [Abstract]
  • Jaiswal, R., Gong, J., Sambasivam, S., Combes, V., Mathys, J., Davey, R., Grau, G., Bebawy, M. (2012), Microparticle-associated nucleic acids mediate trait dominance in cancer. The FASEB Journal. 26(1), 420-429. [Abstract]


  • Stordal, B., Davey, R. (2009), A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Current Cancer Drug Targets. 9(3), 354-365. [Abstract]
  • Stordal, B., Davey, R. (2009), ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair. Cancer chemotherapy and pharmacology. 63(4), 661-72. [Abstract]
  • Bromley, R., Oliver, L., Davey, R., Harvie, R., Baldock, C. (2009), Predicting the clonogenic survival of A549 cells after modulated x-ray irradiation using the linear quadratic model. Physics in medicine and biology. 54(2), 187-206. [Abstract]
  • Stordal, B., Pavlakis, N., Davey, R. (2009), A systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy. In: Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. (pp.225-230).United States: Humana Press.
  • Stordal, B., Davey, R. (2009), Regrowth resistance: low-level platinum resistance mediated by rapid recovery from platinum-induced cell-cycle arrest. In: Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. (pp.171-176).United States: Humana Press.


  • Janneh, O., Hartkoorn, R., Jones, E., Owen, A., Ward, S., Davey, R., Back, D., Khoo, S. (2008), Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. British journal of pharmacology. 155(6), 875-883. [Abstract]
  • Stordal, B., Davey, R. (2008), Platinum resistance needs the mythbusters. Toxicology letters. , 230. [Abstract]
  • Stordal, B., Davey, R. (2008), A 39 kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome. IUBMB Life. 60(3), 180-184. [Abstract]